Thrasos is a private, clinical-stage biotherapeutics company focused on bringing new solutions to kidney disease patients. The company has designed a specific class of peptide compounds that have shown excellent results in controlling experimental kidney diseases, notably, models of diabetic nephropathy (kidney damage associated with diabetes), and acute kidney injury.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.